TY - JOUR
T1 - Coffee intake, recurrence, and mortality in stage III colon cancer
T2 - Results from CALGB 89803 (Alliance)
AU - Guercio, Brendan J.
AU - Sato, Kaori
AU - Niedzwiecki, Donna
AU - Ye, Xing
AU - Saltz, Leonard B.
AU - Mayer, Robert J.
AU - Mowat, Rex B.
AU - Whittom, Renaud
AU - Hantel, Alexander
AU - Benson, Al
AU - Atienza, Daniel
AU - Messino, Michael
AU - Kindler, Hedy
AU - Venook, Alan
AU - Hu, Frank B.
AU - Ogino, Shuji
AU - Wu, Kana
AU - Willett, Walter C.
AU - Giovannucci, Edward L.
AU - Meyerhardt, Jeffrey A.
AU - Fuchs, Charles S.
N1 - Publisher Copyright:
© 2015 American Society of Clinical Oncology. All rights reserved.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Purpose: Observational studies have demonstrated increased colon cancer recurrence in states of relative hyperin-sulinemia, including sedentary lifestyle, obesity, and increased dietary glycemic load. Greater coffee consumption has been associated with decreased risk of type 2 diabetes and increased insulin sensitivity. The effect of coffee on colon cancer recurrence and survival is unknown. Patients and Methods: During and 6 months after adjuvant chemotherapy, 953 patients with stage III colon cancer prospectively reported dietary intake of caffeinated coffee, decaffeinated coffee, and nonherba tea, as well as 128 other items. We examined the influence of coffee, nonherbal tea, and caffeine on cancer recurrence and mortality using Cox proportional hazards regression. Results: Patients consuming 4 cups/d or more of total coffee experienced an adjusted hazard ratio (HR) for colon cancer recurrence or mortality of 0.58 (95% CI, 0.34 to 0.99), compared with never drinkers (Ptrend = .002). Patients consuming 4 cups/d or more of caffeinated coffee experienced significantly reduced cancer recurrence or mortality risk compared with abstainers (HR, 0.48; 95% CI, 0.25 to 0.91; Ptrend = .002), and increasing caffeine intake also conferred a significant reduction in cancer recurrence or mortality (HR, 0.66 across extreme quintiles; 95% CI, 0.47 to 0.93; Ptrend = .006). Nonherbal tea and decaffeinated coffee were not associated with patient outcome. The association of total coffee intake with improved outcomes seemed consistent across other predictors of cancer recurrence and mortality. Conclusion: Higher coffee intake may be associated with significantly reduced cancer recurrence and death in patients with stage III colon cancer.
AB - Purpose: Observational studies have demonstrated increased colon cancer recurrence in states of relative hyperin-sulinemia, including sedentary lifestyle, obesity, and increased dietary glycemic load. Greater coffee consumption has been associated with decreased risk of type 2 diabetes and increased insulin sensitivity. The effect of coffee on colon cancer recurrence and survival is unknown. Patients and Methods: During and 6 months after adjuvant chemotherapy, 953 patients with stage III colon cancer prospectively reported dietary intake of caffeinated coffee, decaffeinated coffee, and nonherba tea, as well as 128 other items. We examined the influence of coffee, nonherbal tea, and caffeine on cancer recurrence and mortality using Cox proportional hazards regression. Results: Patients consuming 4 cups/d or more of total coffee experienced an adjusted hazard ratio (HR) for colon cancer recurrence or mortality of 0.58 (95% CI, 0.34 to 0.99), compared with never drinkers (Ptrend = .002). Patients consuming 4 cups/d or more of caffeinated coffee experienced significantly reduced cancer recurrence or mortality risk compared with abstainers (HR, 0.48; 95% CI, 0.25 to 0.91; Ptrend = .002), and increasing caffeine intake also conferred a significant reduction in cancer recurrence or mortality (HR, 0.66 across extreme quintiles; 95% CI, 0.47 to 0.93; Ptrend = .006). Nonherbal tea and decaffeinated coffee were not associated with patient outcome. The association of total coffee intake with improved outcomes seemed consistent across other predictors of cancer recurrence and mortality. Conclusion: Higher coffee intake may be associated with significantly reduced cancer recurrence and death in patients with stage III colon cancer.
UR - http://www.scopus.com/inward/record.url?scp=84947282178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947282178&partnerID=8YFLogxK
U2 - 10.1200/JCO.2015.61.5062
DO - 10.1200/JCO.2015.61.5062
M3 - Article
C2 - 26282659
AN - SCOPUS:84947282178
SN - 0732-183X
VL - 33
SP - 3598
EP - 3607
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 31
ER -